DRMA (Dermata Therapeutics) Short-Term Debt to Capital

The visualized price action of Dermata Therapeutics (DRMA) reflects the financial standing of a management team focused on a sponge platform, where the indicator stands at 0.00. Meanwhile, the company minimizes its environmental impact through production outsourcing and digital documentation. The business relies on developing innovative drug delivery systems for the therapy of rosacea and acne, aiming to redefine the standards of modern dermatology.

The short-term debt-to-equity ratio measures the proportion of liabilities maturing within one year in the financing structure, determining liquidity risk and overall financial stability. For Dermata Therapeutics (DRMA), which invests in the deep penetration of topical drugs, this metric is critical, as excessive leverage could restrict R&D activity, a trend clearly reflected in this short-term debt-to-equity chart.